tirzepatide

Overview

Tirzepatide is a novel pharmacological agent that functions as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This unique mechanism of action positions tirzepatide as a significant therapeutic option for the management of obesity and type 2 diabetes. By enhancing insulin secretion, reducing appetite, and promoting weight loss, tirzepatide addresses key metabolic dysfunctions associated with these conditions. Its efficacy in promoting weight loss and improving cardiometabolic health has garnered attention in recent clinical studies, highlighting its potential role in obesity management and related comorbidities.

Recent Publications Focus

Below is a summary of the newest research publications targeting tirzepatide (sorted by publication date).

Recent studies have continued to evaluate tirzepatide in real-world and trial-based settings across obesity, type 1 diabetes, and cardiometabolic risk. In adults with type 1 diabetes and obesity, a retrospective cohort study found that tirzepatide was associated with significant improvements in HbA1c, body weight, and total daily insulin dose over 12 months compared with matched controls, along with favorable changes in blood pressure and lipid markers. Safety outcomes were reassuring, with no between-group difference in severe hypoglycaemia, ketoacidosis, or hospitalisation rates, and most participants remained on treatment at 1 year. A separate retrospective cohort study in people with type 1 diabetes and overweight or obesity also examined effects on body weight, glycaemic control, insulin requirements, continuous glucose monitoring metrics, and cardiorenal parameters.

Other recent publications have focused on tirzepatide’s role in obesity management and post-procedural weight regain. A real-world study evaluated tirzepatide for recurrent weight gain after bariatric surgery or endoscopic bariatric therapy, reflecting growing interest in its use after weight-loss procedures. A multicentre observational study assessed 6-month effectiveness, persistence, and safety of low- to moderate-dose tirzepatide in adults with obesity, while a post-hoc analysis of SURMOUNT-1 examined shifts in waist-to-height ratio categories among adults with obesity or overweight, with or without prediabetes. A network meta-analysis compared tirzepatide with semaglutide, cagrilintide, and CagriSema for overweight and obesity, and a commentary on ICER’s assessment highlighted tirzepatide’s weight-loss and cardiometabolic benefits alongside access and affordability challenges.

Several publications addressed safety, pharmacovigilance, and special populations. One retrospective study of 527 patients receiving tirzepatide for 12 months reported new or worsening thyroid disease in 5.3% of patients, with baseline thyroid disease and end-stage renal disease identified as significant risk factors. A pharmacovigilance analysis of GLP-1 receptor agonist adverse event reports found that tirzepatide had negative log-transformed reporting odds ratios for several gastrointestinal events, while another population-based observational study detected a signal for muscle atrophy reporting with tirzepatide. A separate report warned of a novel impurity in mass-compounded tirzepatide/B12 products, underscoring potential patient safety concerns.

Beyond metabolic disease, tirzepatide has also been explored in broader cardiometabolic and neurodegenerative contexts. A pre-specified exploratory analysis from SURPASS-CVOT evaluated major kidney events in people with type 2 diabetes and atherosclerotic cardiovascular disease, building on prior findings that tirzepatide was non-inferior to dulaglutide for the primary cardiovascular outcome. Additional studies examined tirzepatide in relation to cardiovascular-kidney-metabolic stage progression, gestational diabetes risk after pre-pregnancy exposure, and comparative neurocognitive outcomes versus semaglutide in type 2 diabetes. Preclinical work also reported that tirzepatide attenuated neurotoxicity in an Alzheimer’s disease-like rat model and inhibited toxic amyloid-β42 aggregation in vitro, suggesting possible mechanisms relevant to Alzheimer’s disease that remain exploratory and require further validation.

Background PMIDs

• [PMID 41885866]

Target PMIDs

• [PMID 41344888]
• [PMID 41825212]
• [PMID 41852165]
• [PMID 41864088]
• [PMID 42009260]
• [PMID 42010938]
• [PMID 42037110]
• [PMID 42082865]
• [PMID 42097660]
• [PMID 42098901]
• [PMID 42114520]
• [PMID 42125916]
• [PMID 42133988]
• [PMID 42145153]
• [PMID 42154338]
• [PMID 42166309]
• [PMID 42207966]
• [PMID 42247124]
• [PMID 42286047]
• [PMID 42348222]
• [PMID 42363996]
• [PMID 42387290]
• [PMID 42410316]